Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study

Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Shinsuke Yasuda, Naoto Tamura, Keishi Fujio, Takao Fujii, Toshihisa Kojima, Tatsuhiko Anzai, Chikuma Hamada, Yoshihisa Fujino, Shinya Matsuda, Hitoshi Kohsaka

Research output: Contribution to journalArticle

Abstract

Objectives: We evaluated long-term control of rheumatoid arthritis (RA) in Japanese paid workers (PWs) and house workers (HWs) treated with subcutaneous tocilizumab (TCZ-SC) and explored factors affecting response to TCZ-SC regarding work productivity. Methods: This study collected data from patients with RA in the TCZ-SC +/− conventional synthetic disease-modifying antirheumatic drugs group. Factors affecting the response to tocilizumab regarding work productivity were explored using logistic regression. Differences in quality-adjusted life years (QALYs) between with/without response were analysed by a linear regression. Results: Data were analysed for 357/360 patients. Patients with a ≥ 75% improvement in activity impairment (AI) were considered responders. EuroQol-5 Dimension (EQ-5D), six-item Kessler psychological distress scale score (K6), Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient’s disease global health by visual analogue scale were significant contributors to TCZ-SC response based on improvements in AI. Work Functioning Impairment Scale, presenteeism, EQ-5D, K6, and HAQ-DI significantly contributed to the improvement of overall work impairment in PWs. Shorter disease duration also was related to TCZ-SC response based on AI improvements. Responders had significantly larger mean QALYs than non-responders (difference = 0.2614; p <.001). Conclusions: These real-world clinical data support long-term work productivity control with TCZ-SC for biologic-naïve HWs and PWs with RA.

Original languageEnglish
JournalModern rheumatology
DOIs
Publication statusAccepted/In press - 2020 Jan 1

    Fingerprint

Keywords

  • Activity impairment
  • patient-reported outcome
  • rheumatoid arthritis
  • tocilizumab
  • work productivity

ASJC Scopus subject areas

  • Rheumatology

Cite this

Tanaka, Y., Kameda, H., Saito, K., Kaneko, Y., Tanaka, E., Yasuda, S., Tamura, N., Fujio, K., Fujii, T., Kojima, T., Anzai, T., Hamada, C., Fujino, Y., Matsuda, S., & Kohsaka, H. (Accepted/In press). Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. Modern rheumatology. https://doi.org/10.1080/14397595.2019.1709681